Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets
- PMID: 10358196
Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets
Abstract
A casein kinase released from activated human platelets phosphorylates a number of plasma proteins extracellularly, and that activation of platelets in systemic lupus erythematosus patients parallels an increase in the phosphate content of plasma proteins, including C3. The present study was undertaken to characterize this platelet protein kinase and to further elucidate the effect(s) on C3 function of phosphorylation by platelet casein kinase. The phosphate content of human plasma C3 was increased from 0.15 to 0.60 mol phosphate/mol of C3 after platelet activation in whole blood or platelet-rich plasma. The platelet casein kinase was distinct from other casein kinases in terms of its dependence on cations, inhibition by specific protein kinase inhibitors, and immunological reactivity. C3 that had been phosphorylated with platelet casein kinase was tested for its susceptibility to cleavage by trypsin or the classical and alternative pathway convertases and its binding to EAC and IgG. Phosphorylation did not affect the cleavage of C3 into C3a and C3b, but the binding of fragments from phosphorylated C3 to EAC14oxy2 cells and to IgG in purified systems and in serum was increased by 1.6-4.5 times over that of unphosphorylated C3. A covariation was seen between the enhanced binding of C3 fragments to IgG after phosphorylation and an increased ratio of glycerol/glycine binding, from 2.0 for unphosphorylated C3 to 4.9 for phosphorylated C3. The present study suggests that an overall effect of phosphorylation of C3 by platelet casein kinase is to enhance the opsonization of immune complexes.
Similar articles
-
Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.Eur J Immunol. 2001 Apr;31(4):1047-54. doi: 10.1002/1521-4141(200104)31:4<1047::aid-immu1047>3.0.co;2-y. Eur J Immunol. 2001. PMID: 11298329
-
Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.J Immunol. 1996 Jul 15;157(2):884-91. J Immunol. 1996. PMID: 8752942
-
Phosphorylation of coagulation factor XI by a casein kinase released by activated human platelets increases its susceptibility to activation by factor XIIa and thrombin.Thromb Haemost. 1999 Oct;82(4):1283-8. Thromb Haemost. 1999. PMID: 10544914
-
The tick-over theory revisited: is C3 a contact-activated protein?Immunobiology. 2012 Nov;217(11):1106-10. doi: 10.1016/j.imbio.2012.07.008. Immunobiology. 2012. PMID: 22964236 Review.
-
An affinity for complement C3 as a possible reason for the potency of naturally occurring antibodies in mediating tissue homeostasis.Beitr Infusionsther. 1989;24:193-9. Beitr Infusionsther. 1989. PMID: 2481539 Review.
Cited by
-
The "ins and outs" of complement-driven immune responses.Immunol Rev. 2016 Nov;274(1):16-32. doi: 10.1111/imr.12472. Immunol Rev. 2016. PMID: 27782335 Free PMC article. Review.
-
Identification of phosphorylated proteins in erythrocytes infected by the human malaria parasite Plasmodium falciparum.Malar J. 2009 May 18;8:105. doi: 10.1186/1475-2875-8-105. Malar J. 2009. PMID: 19450262 Free PMC article.
-
Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection.Transplant Rev (Orlando). 2009 Jul;23(3):139-50. doi: 10.1016/j.trre.2009.02.005. Epub 2009 Apr 10. Transplant Rev (Orlando). 2009. PMID: 19362461 Free PMC article.
-
Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease.Clin Vaccine Immunol. 2007 May;14(5):549-55. doi: 10.1128/CVI.00486-06. Epub 2007 Mar 7. Clin Vaccine Immunol. 2007. PMID: 17344343 Free PMC article. Clinical Trial.
-
Complement in Hemolysis- and Thrombosis- Related Diseases.Front Immunol. 2020 Jul 10;11:1212. doi: 10.3389/fimmu.2020.01212. eCollection 2020. Front Immunol. 2020. PMID: 32754149 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases
Miscellaneous